Ontology highlight
ABSTRACT:
SUBMITTER: Manzini C
PROVIDER: S-EPMC5308621 | biostudies-literature | 2016 Sep
REPOSITORIES: biostudies-literature
Manzini Claudia C Venè Roberta R Cossu Irene I Gualco Marina M Zupo Simonetta S Dono Mariella M Spagnolo Francesco F Queirolo Paola P Moretta Lorenzo L Mingari Maria Cristina MC Pietra Gabriella G
Oncotarget 20160901 38
Oncogene-targeted therapies based on mutated BRAF- and/or MEK-specific inhibitors have been developed for melanoma treatment. Although these drugs induce tumor regression in a high percentage of patients, clinical responses are frequently limited in time and tumors often recur. Recent studies suggested that the combination of BRAF/MEK inhibition with immunotherapy could represent a promising strategy for the cure of melanoma. NK cells are suitable effectors for tumor immunotherapy. Here we show ...[more]